• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Halozyme Therapeutics downgraded by Leerink Partners with a new price target

    5/13/25 8:55:01 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email
    Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and set a new price target of $47.00
    Get the next $HALO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    6/7/2024$48.00 → $51.00Overweight → Neutral
    Piper Sandler
    2/29/2024$54.00Outperform
    TD Cowen
    7/24/2023$61.00Buy
    H.C. Wainwright
    7/24/2023$43.00 → $45.00Buy → Neutral
    Goldman
    More analyst ratings

    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Halozyme Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equal-Weight and set a new price target of $62.00

      5/14/25 8:56:30 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and set a new price target of $47.00

      5/13/25 8:55:01 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously

      10/7/24 8:32:56 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Leadership Updates

    Live Leadership Updates

    See more
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • Mahesh Krishnan Elected to Halozyme's Board of Directors

      SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.

      4/25/24 4:45:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Appoints Barbara Duncan to its Board of Directors

      SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan

      2/6/23 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care